Updated from 4:12 p.m. EDT
Seracare Life Sciences
was among the best-performing health care stocks Monday after the San Diego biological products company announced late Friday that it obtained commitments for equity financing.
The company entered into an agreement to raise about $8.16 million from the sale of its stock in a private placement. The agreement is contingent upon Seracare closing its previously announced acquisition of BBI Diagnostics and BBI Biotech Research Labs. The investors have placed $8.16 million in escrow pending the outcome of the acquisitions. Seracare agreed to sell 800,000 shares at a discounted price of $10.20 a share. Shares of Seracare Life Sciences traded up 60 cents, or 5%, to $12.70.
rose after it entered into a research and development agreement with
. The two companies will develop imaging diagnostic tools and personalized medications for the treatment of cancer. The two companies will share costs and responsibilities, as well as value that is derived from the commercialization of products. Shares of Celera Genomics traded up 46 cents, or 4.3%, to $11.26.
traded actively after the company received fast-track status from the Food and Drug Administration for its Pixantrone drug. The drug was granted fast-track status as a result of its strong showing in phase I and phase II testing. Shares of Cell Therapeutics traded up 5 cents, or 0.8%, to $6.63.
rose after the U.S. National Institute of Justice awarded the company an exclusive contract to create genetic profiles from DNA samples from felons in Illinois, which will be added to the FBI's Combined DNA Index System. The one-year, multimillion-dollar contract was awarded after a competitive bid process. The tests will ultimately cover some 100,000 felons. Shares of Orchid BioSciences traded up 5 cents, or 0.7%, to $7.45.
Other health care volume movers included
, down 38 cents to $33.62;
, down $1.44 to $47.50;
, up 37 cents to $53.98;
, up 2 cents to $51.37; and
, down 52 cents to $17.55.